Mustang Bio Announces Updated Interim Data on X-Linked : com

All 23 treated patients are alive at 2.6-year median follow-up without evidence of malignant transformation Data representing largest cohort of infants...

Related Keywords

United States , San Francisco , California , American , Jaclyn Jaffe , Ewelina Mamcarz , Manuel Litchman , Tony Plohoros , Department Of Bone Marrow Transplantation , Company Contacts , Lifesci Advisors , Company Investigational New Drug , National Institute Of Allergy , National Institutes Of Health , Jude Children Research Hospital St , Mustang Bio Inc , Nasdaq , Exchange Commission , Securities Exchange , Fortress Biotech Inc , Annual Meeting , American Society , Investigational New Drug , Bone Marrow Transplantation , Cellular Therapy , Jude Children , Research Hospital , Clinical Trials Spotlight Symposium , Cell Therapy , Seattle Children , National Institute , Infectious Diseases , National Institutes , Chief Executive Officer , X Linked Severe Combined Immunodeficiency , Securities Exchange Act , Fortress Biotech , Looking Statements , Securities Act , Annual Report , Private Securities Litigation Reform Act , Relations Contact , Sci Advisors , Nasdaq Mbio , Mustang Bio , Nc , Sgct 2022 , Dscid , St Jude , Lentiviral Gene Therapy ,